Comments for Icarus Consultants

Comment on Strategy Consulting Capabilities by Pharma Conference Coverage and Medical Meetings Strategy | Icarus Consultants

Mon, 23 Jan 2012 12:43:53 +0000

[...] Capabilities [...]

Comment on Management Team by Future of Alzheimer’s is biomarkers & preclinical diagnosis | Icarus Consultants

Tue, 03 Jan 2012 22:49:01 +0000

[...] Management [...]

Comment on Key Opinion Leader (KOL) Market Research by NYAS event on pathogenesis of cancer and inflammation | Icarus Consultants

NYAS event on pathogenesis of cancer and inflammation | Icarus Consultants — Tue, 03 Jan 2012 22:46:52 +0000

[...] provide the chance to network and meet key opinion leaders (KOL). Icarus Consultants undertakes KOL market research, and personal relationships are often key to obtaining access to physicians and researchers with [...]

Comment on New Products Commercial Strategy, Pathway and Competitor Analysis by CRKL may be a new molecular target in lung cancer | Icarus Consultants

CRKL may be a new molecular target in lung cancer | Icarus Consultants — Fri, 28 Oct 2011 14:58:02 +0000

[...] molecular target in lung cancer Posted on October 28, 2011 by Daedalus One of the services that Icarus Consultants offers pharma & biotech companies is help in identifying molecular [...]

Comment on Market Opportunity, Therapeutic Area and Commercial Landscape Analysis by Understanding the Pharma Biotech Competitive Landscape | Icarus Consultants

Understanding the Pharma Biotech Competitive Landscape | Icarus Consultants — Mon, 03 Oct 2011 19:40:24 +0000

[...] Understanding the Pharma Biotech Competitive Landscape Posted on October 3, 2011 by Daedalus One of the pharma marketing strategy consulting services that we offer clients is a competitive landscape, market opportunity report. [...]

Comment on Conference Schedule by Pharma Cancer Conference Coverage: the week in review | Icarus Consultants

Pharma Cancer Conference Coverage: the week in review | Icarus Consultants — Fri, 09 Sep 2011 14:02:01 +0000

[...] Conferences [...]

Comment on Is the current model of cancer drug development sustainable? by Pfizer Xalkori crizotinib price in line with Zelboraf cost | Icarus Consultants

Tue, 30 Aug 2011 06:52:50 +0000

[...] high price of recently approved oncology drugs such as Zelboraf, Adcetris and Xalkori represents a sustainable business model in the long-run. Drug companies argue that how society spends its healthcare dollars is a matter [...]

Comment on Management Team by Sally Church invited to speak at MD Anderson Cancer Center | Icarus Consultants

Mon, 29 Aug 2011 17:34:16 +0000

[...] Who are we? [...]

Comment on Analyzing the cost of Seattle Genetics Adcetris (brentuximab vedotin) by Pfizer Xalkori crizotinib price in line with Zelboraf cost | Icarus Consultants

Mon, 29 Aug 2011 12:47:40 +0000

[...] it remains to be seen whether the high price of recently approved oncology drugs such as Zelboraf, Adcetris and Xalkori represents a sustainable business model in the long-run. Drug companies argue that [...]

Comment on Zelboraf (vemurafenib) approved in metastatic melanoma by Pfizer Xalkori crizotinib price in line with Zelboraf cost | Icarus Consultants

Mon, 29 Aug 2011 12:47:05 +0000

[...] results, it remains to be seen whether the high price of recently approved oncology drugs such as Zelboraf, Adcetris and Xalkori represents a sustainable business model in the long-run. Drug companies [...]